Search In this Thesis
   Search In this Thesis  
العنوان
Assessment of cardiac functions
before and after treatment of Egyptian
chronic hepatitis C patients using
directly acting antivirals /
المؤلف
Talkhan,Mohamed Gamal Tawfik.
هيئة الاعداد
باحث / Mohamed Gamal Tawfik Talkhan
مشرف / Khaled Hamdy Abd-Almaged
مشرف / Hesham Hamdy Radwan
مشرف / Eslam Safwat Mohamed
تاريخ النشر
2020
عدد الصفحات
178P.:
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الطب الباطني
تاريخ الإجازة
1/1/2020
مكان الإجازة
جامعة عين شمس - كلية الطب - الباطنة العامة
الفهرس
Only 14 pages are availabe for public view

from 178

from 178

Abstract

To this day, hepatitis C virus infection represents a global
burden. The long term impact of HCV infection is
highly variable, ranging from minimal effects to severe extrahepatic
complications. In light of the advances in HCV
therapy and treatment, monitoring is required to ensure safety
of newly administrated regimens to patients.
The aim of this study was to investigate possible
cardiac effects of direct antiviral drugs on Egyptian HCV
patients.
Patients were divided into 2 groups: group 1: 45 noncirrhotic
patients received treatment with Sofosbuvir +
Daclatasvir for 12 weeks. group 2: 45 cirrhotic patients
received treatment with Sofosbuvir + Daclatasvir + ribavirin
for 12 weeks. All patient achieved sustained virologic
response at week 12 after end of treatment (SVR12). All
patients were assessed at week 0 (start of treatment) and
week 12 after end of treatment(SVR 12) with laboratory
studies including level of NT- Pro BNP, ultrasonography,
Echocardiography. Also, study population was divided into 2
groups: Risky group: include patients above 50 yrs. old,
Diabetics, prediabetics, obese (BMI >25 kg/m²),
hypertensives, hyperlipidemia patients and smokers. Non- Risky group: include patients who have no CVD risk factors
mentioned before.
In this study statistical analysis of data showed no
changes concerning either laboratory findings ‘liver functions
Albumin, Bilirubin, INR & CBC’ or radiological findings ‘by
abdominal ultra sound & fibro-scan’ in the study groups after
clearing the virus at end of treatment, after 3 months post
treatment except for AST and ALT. Liver enzymes including
AST and ALT decreased significantly after achieving SVR.
No significant changes in ECG parameters in both
groups after achieving SVR were documented.
NT-Pro BNP significantly increased after treatment with
DAAs in both groups (cirrhotic and non-cirrhotic) and the same
finding was noted in the risky group.
Echocardiographic assessment of systolic and diastolic
functions, dimensions and volumes of LV and RV revealed
no significant changes in assessment parameters before and
after treatment with DAAs in all studied groups. There was a
negative correlation between change in Hb and change in
NT-Pro BNP in cirrhotic group.We concluded that the treatments for DAAs used in
combination regimens do not affect the cardiovascular
system markedly. However, minor subclinical myocardial
affection may occur especially in risky group for CVD.